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Clinical Characteristics and Risk Factors for Fatality in Patients 
with Bloodstream Infections Caused by Glucose Non-fermenting 
Gram-negative Bacilli
Tzu-Yao Chang, Chen-Hsiang Lee, Jien-Wei Liu*
Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center,
 Chang Gung University College of Medicine, Kaohsiung, Taiwan.
BACKGROUND/PURPOSE: Glucose non-fermenting Gram-negative bacilli (GNF-GNB) bloodstream 
infections (BSIs) are often hospital-acquired and are important causes of morbidity and mortality. Our 
objectives were to evaluate the epidemiology and clinical characteristics of GNF-GNB BSIs, and to 
identify risk factors for fatality.
METHODS: We retrospectively reviewed cases of GNF-GNB BSIs in adult patient (≥ 18 years of age) 
hospitalized between January and December 2005.
RESULTS: A total 221 GNF-GNB bacteremic episodes (200 hospital-acquired and 21 community-acquired) 
in 215 patients (123 men and 92 women; mean age, 63.38 ± 16.10 years) were included in our study. Of these, 
52.5% were elderly (age > 65). Malignancy (43.0%), diabetes mellitus (22.6%) and steroid use (22.6%) were the 
major underlying diseases/conditions. Central venous catheter (CVC) placement had been carried out in 
57.5% of patients. The 28-day mortality was significantly higher in those patients with: liver cirrhosis, steroid 
use, pneumonia as the primary source of infection, intensive care unit-acquired infections, septic shock, and 
a high Pitt bacteremia score (≥ 4 points). Liver cirrhosis [odds ratio (OR) = 6.4; 95% confidence interval 
(CI) = 1.7–23.9; p < 0.01)], hematologic malignancy (OR = 3.9; 95% CI = 1.1–14.1; p = 0.04), pneumonia 
(OR = 4.0; 95% CI = 1.4 – 11.0; p < 0.01), septic shock (OR = 13.0; 95% CI = 4.6–36.6; p < 0.01), and intensive care 
unit-acquired infections (OR = 2.9; 95% CI = 1.1–8.0; p = 0.04) were all independent risk factors for fatality.
CONCLUSION: Our data suggested that CVC placement and steroid use predispose to GNF-GNB bactere-
mia. Early removal of CVC and avoidance of steroids may minimize the chances of acquiring this infection, 
which is of particular importance for patients at high risk of mortality once they are infected with GNF-GNB.
KEYWORDS: bloodstream infection, clinical characteristics, fatality, glucose non-fermenting bacilli, 
risk factors
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Introduction
Bloodstream infections (BSIs) caused by Gram-negative 
bacilli (GNB) are reported to constitute approximately 50% 
of nosocomial BSIs.1 These GNB comprise members of the 
Enterobacteriaceae family and glucose non-fermenting 
Gram-negative bacilli (GNF-GNB). GNF-GNB may in-
clude Pseudomonas aeruginosa and other Pseudomonas species, 
Acinetobacter spp., Stenotrophomonas maltophilia, Alcaligenes 
spp., Flavimonas oryzihabitans, and Sphingobacterium spp. 
etc.2–4 It is notable that P. aeruginosa is one of the most 
prevalent pathogens in nosocomial BSIs.2,3 These patho-
genic GNF-GNB are characterized by their resistance to 
multiple antibiotics and often contaminate the hospital en-
vironment, medical equipment and the skin of healthcare 
workers. They often cause infections in seriously ill hospi-
talized patients, resulting in a high mortality rate among 
these patients.5,6 To better understand the risk factors for 
acquisition of GNF-GNB bacteremia and the outcomes for 
the affected patients, this study was designed to investigate 
the epidemiology and clinical characteristics of GNF-GNB 
BSIs, and to identify risk factor(s) for fatality in infected 
patients.
Methods
We performed a retrospective study in adult patients (≥ 18 
years of age) admitted to Chang Gung Memorial Hospital 
Kaohsiung (CGMH-KS) between January and December 
2005. CGMH-KS is a 2,500-bed primary care and tertiary 
referral center in Southern Taiwan. The patients with 
GNF-GNB BSIs included in the study were chosen from 
the computerized database of the hospital’s clinical 
microbiology laboratory. A repeated GNF-GNB bactere-
mia that occurred more than 2 weeks apart from the 
previous one was regarded as a new GNF-GNB bactere-
mia. The medical charts of patients were reviewed and de-
mographic, clinical and laboratory information were 
collected.
The bacteremia was defined as hospital-acquired if it 
occurred 72 hours or more after admission, and/or if the 
affected patient had been hospitalized in the 2 weeks be-
fore the current admission. Intensive care unit (ICU)-
acquired bacteremia was defined as occurring 72 hours 
or more after admission to the ICU. Any case in which 
additional microbes other than GNF-GNB were isolated 
from blood cultures was regarded as a polymicrobial bac-
teremia. The source of the BSI in each patient was deter-
mined on a clinical basis. Sources of BSI such as lung, 
urinary tract, biliary tract and intra-abdominal were de-
fined as previously described.7 A case was regarded as a 
primary bacteremia when no overt infection focus other 
than the bloodstream was identified. Catheter-related 
bacteremia was defined as isolation of the same organism 
from blood cultures and from semiquantitative cultures 
of a catheter segment (> 15 CFU/tip culture), accompanied 
by the clinical syndrome of bloodstream infection in the 
absence any other apparent source.8 Renal failure was de-
fined as a serum creatinine level > 2.0 mg/dL, or levels sim-
ilar to those of a patient receiving regular hemodialysis. 
Diabetes mellitus was defined by one of the following cri-
teria: (1) random plasma glucose level > 200 mg/dL; (2) 
plasma glucose of 126 mg/dL, or greater after overnight 
fast on recovery from sepsis; and (3) being previously di-
agnosed as a diabetic and taking oral anti-diabetic agents, 
or receiving insulin injections. Hematological malignancy 
was defined as lymphoma, acute or chronic leukemia, or 
multiple myeloma diagnosed by a hematologist. The Pitt 
bacteremia score was used to assess the illness severity of 
patients,9,10 and was calculated according to the following 
criteria: (1) oral temperature: 2 points for a temperature 
of ≤ 35ºC or ≥ 40ºC, 1 point for a temperature 35.1–36.0ºC 
or 39.0–39.9ºC; (2) hypotension: 2 points for an acute hypo-
tensive event with decreases in systolic (> 30 mmHg) and di-
astolic (> 20 mmHg) blood pressure, the use of intravenous 
vasopressor agents, or systolic blood pressure < 90 mmHg; 
(3) receipt of mechanical ventilation: 2 points; (4) cardiac 
arrest: 4 points; and (5) mental status: alert, 0 points; dis-
oriented, 1 point; stuporous, 2 points; and comatose, 
4 points. Critical illness was defined as a Pitt bacteremia 
score of ≥ 4 points.9 Antibiotic therapy, started on an em-
pirical basis upon suspicion of sepsis, was considered ap-
propriate if the pathogen grown from blood cultures was 
susceptible in vitro to the prescribed antimicrobial agent(s), 
and was started within 48 hours after the blood was sam-
pled for culture. Antibiotic therapy was regarded as effec-
tive if treatment with the appropriate antimicrobial(s) was 
carried out for at least 1 week. Steroid use was defined as 
use of prednisolone (≥ 10 mg/day), or other equivalent 
steroid, for at least 2 weeks before the development of 
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bacteremia. The endpoint for the assessment of fatality 
was death within 28 days of developing a GNF-GNB bac-
teremia. A fatality was considered to be directly related 
GNF-GNB-bacteremia if the case involved a patient who 
died of unrelenting sepsis within 28 days after his or her 
blood had been sampled for culture, and GNF-GNB was 
isolated from that culture.
The protocols for sampling blood for culture in patients 
suspected of having bacteremia and the general handling of 
blood specimens within CGMH-KS follows: Briefly, at 
least two blood samples were drawn (approximately 8 mL) 
into a Plus Aerobic/F bottle and a Standard Anaerobic/F 
bottle (as monitored by the BACTEC 9240 instrument; 
Becton-Dickinson Microbiology System, Becton Dickinson, 
MD, USA). The bottles were then incubated at 35ºC. 
Cultures were regarded as negative if no bacterial growth 
had occurred within 7 days. GNF-GNB was identified using 
standard methods11 and was verified using the automated 
ID 32GN System (BioMérieux, Vitek, Hazelwood, MO, 
USA). Antimicrobial susceptibility testing was performed 
on a clinical service basis using the disk diffusion method, 
and using interpretative criteria for non-fermentative 
Gram-negative rods.12
Patients were divided into non-fatal and fatal groups. 
The Student’s t test or the Mann-Whitney U test was used 
for comparison of continuous variables, and the χ2 test or 
Fisher’s exact test was used for comparison of dichoto-
mous variables when analyzing the differences between 
variables in patients with hospital-acquired and commu-
nity-acquired GNF-GNB bacteremia, as well as the differ-
ences between variables in patients in the non-fatal and 
fatal groups. Differences between the non-fatal and fatal 
groups with a p value < 0.1 were entered into a logistic re-
gression model to determine the independent factor(s) 
for fatality. A p value of < 0.05 was considered to be statis-
tically significant. All statistical analyses were performed 
using the SPSS version 13.0 ( SPSS Inc., Chicago, IL, 
USA).
Results
A total 221 GNF-GNB bacteremic episodes (200 hospital-
acquired and 21 community-acquired) in 215 patients 
(123 men and 92 women; mean age, 63.38 ± 16.10 years) 
were included in the study. As shown in the Figure, 
the three most commonly isolated GNF-GNB organisms 
were P. aeruginosa (124 episodes; 55.6%), A. baumannii (39 
episodes; 17.5%), and S. maltophilia (20 episodes, 9.0%). Of 
the 221 cases of GNF-GNB bacteremia, 62 were polymicro-
bial, the concurrent pathogens being Enterobacte riaceae 
(n = 40), staphylococci (n = 17), enterococci (n = 8), strepto-
cocci (n = 5) and anaerobes (n = 4). Of the 40 cases of co-
infection with Enterobacteriaceae, Escherichia coli (n = 14) 
and Klebsiella pneumoniae (n = 7) were the most common.
The demographic and clinical characteristics of the 
patients infected with GNF-GNB bacteremic are summa-
rized in Table 1. The three most common underlying 
diseases/conditions were solid tumors (71/221; 32.1%), dia-
betes mellitus (50/221; 22.6%), and steroid use (50/221; 
22.6%). Of the 200 hospital-acquired GNF-GNB bacteremic 
episodes, 85 (42.5%) occurred in ICU (ICU-acquired). 
Regarding the use of invasive procedures; 127/221 (57.5%) 
episodes had a central venous catheter (CVC) placement 
when bacteremia developed. The three most frequently 
encountered infection sources among the 221 GNF-GNB 
bacteremic episodes were lung (n = 49; 22.2%), urinary 
tract (n = 33; 14.9%) and biliary tract (n = 25; 11.3%). Of the 
221 GNF-GNB infections included in the study, there 
were 79 (35.7%) episodes in which the affected patients 
were found to be critically ill (Pitt bacteremia score ≥ 4), 
and there were 56 (25.3%) episodes of septic shock.
Eighty patients died, giving an overall mortality rate 
of 36.2%. Fifty-seven (25.8%) of the fatalities were directly 
Figure. Glucose non-fermenting Gram-negative bacilli found 
in 221 bacteremic episodes. Others included Schewanella spe-
cies (n = 3), Sphingobacterium species (n = 1), Brevudimonas species 
(n = 1), Chryseomonas species (n = 2) and unidentified species 
(n = 11).
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Table 1. Demographic and clinical characteristics of 221 episodes of glucose non-fermenting Gram-negative bacillus bacteremiaa
Variable Total (n = 221) Hospital-acquired (n = 200) Community-acquired (n = 21)
Age (yr)
 18–45 31 (14.0) 29 (14.5) 2 (9.5)
 46–55 33 (14.9) 29 (14.5) 4 (19.0)
 56–65 41 (18.6) 38 (19.0) 3 (14.3)
 > 65 116 (52.5) 104 (52.0) 12 (57.1)
Underlying disease/condition
 Diabetes mellitus 50 (22.6) 46 (23.0) 4 (19.0)
 Liver cirrhosis 21 (9.5) 20 (10.0) 1 (4.8)
 Renal failure 32 (14.5) 30 (15.0) 2 (9.5)
 Solid tumor 71 (32.1) 64 (32.0) 7 (33.3)
 Hematologic malignancy 24 (10.9) 23 (11.5) 1 (4.8)
 Neutropenia 16 (7.2) 14 (7.0) 2 (9.5)
 Steroid use 50 (22.6) 50 (25.0) 0 (0)
 Organ transplant 3 (1.4) 3 (1.5) 0 (0)
 CVC placement 127 (57.5) 127 (63.5) 0 (0)
Infection source
 Pneumonia 49 (22.2) 45 (22.5) 4 (19.0)
 Urinary tract infection 33 (14.9) 27 (13.5) 6 (28.6)
 CVC-related infection 22 (10.0) 22 (11.0) 0 (0)
 Biliary tract infection 25 (11.3) 23 (11.5) 2 (9.5)
 Intra-abdominal infection 14 (6.3) 11 (5.5) 3 (14.3)
 Surgical site infection 8 (3.6) 7 (3.5) 1 (4.8)
 CNS infection 1 (0.5) 1 (0.5) 0 (0)
 Primary bacteremia 62 (28.1) 58 (29.0) 4 (19.0)
aData presented as n (%) and one patient might have more than one underlying disease/condition. CNS = Central nervous system; CVC = 
central venous catheter.
related to GNF-GNB bacteremia. Twenty-three deaths 
were not considered to be directly related to GNF-GNB 
bacteremia, but to other events such as massive active gas-
trointestinal bleeding, hemoptysis, progressive intracranial 
hemorrhage or the development of sepsis caused by other 
pathogens after effective therapy for GNF-GNB bactere-
mia initially yielded an apparent clinical improvement. 
Comparisons between the 114 patients who survived and 
the 57 patients who died from GNF-GNB bacteremia are 
summarized in Table 2. Patients in the fatal group had a 
significantly higher proportion of liver cirrhosis (17.5% vs. 
5.7%; p = 0.01), steroid use (38.6% vs. 17.0%; p < 0.02), GNF-
GNB bacteremia secondary to pneumonia (38.6% vs. 12.1%; 
p < 0.01), ICU-acquired GNF-GNB bacteremia (50.9% vs. 
31.9%; p = 0.02), septic shock (59.6% vs. 9.9%; p < 0.01) and a 
Pitt bacteremia score ≥ 4 points (49.1% vs. 22.7%; p < 0.01) 
compared with those in the non-fatal group. In contrast, 
patients in the non-fatal group had a significantly higher 
incidence of GNF-GNB bacteremia secondary to urinary 
tract infections (19.9% vs. 5.3%; p < 0.01) compared with 
those in the fatal group. Notably, no significant differences 
were found in the number of polymicrobial bacteremia 
cases, or the administration of inappropriate empirical 
antibiotic therapy, between the non-fatal and fatal groups. 
Also, there was no significant differences in the causative 
agent; P. aeruginosa, A. baumannii, or S. maltophilia. Logistic 
regression showed that liver cirrhosis (OR = 6.4; 95% 
CI = 1.7–23.9; p < 0.01), hematologic malignancy (OR = 3.9; 
95% CI = 1.1–14.1; p = 0.04), pneumonia as the primary 
source of infection (OR = 4.0; 95% CI = 1.4–11.0; p < 0.01), 
septic shock (OR = 13.0; 95% CI = 4.6–36.6; p < 0.01) and 
ICU-acquired infection (OR = 2.9; 95% CI = 1.1–8.0; p = 0.04) 
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Table 2. Demographic and clinical information of patients involving 198 glucose non-fermenting Gram-negative bacillus bacteremic 
episodesa
Variable Non-fatal (n = 141) Fatal (n = 57) p
Age (yr) 63.2 ± 16.8 62.7 ± 15.6 0.84
Sex, male 72 (51.1) 39 (68.4) 0.03
Underlying disease/condition   
 Diabetes mellitus 34 (24.1) 11 (19.3) 0.58
 Liver cirrhosis 8 (5.7) 10 (17.5) 0.01
 Renal failure 20 (14.2) 10 (17.5) 0.66
 Solid tumor 37 (24.2) 23 (40.4) 0.06
 Hematologic malignancy 13 (9.2) 10 (17.5) 0.14
 Neutropenia 9 (6.4) 6 (10.5) 0.38
 Steroids use 24 (17.0) 22 (38.6) < 0.02
 Organ transplant 1 (0.7) 1 (1.8) 0.45
Infection source   
 Pneumonia 17 (12.1) 22 (38.6) < 0.01
 Urinary tract infection 28 (19.9) 3 (5.3) < 0.01
 CVC-related infection 18 (12.8) 3 (5.3) 0.14
 Biliary tract infection 20 (14.2) 4 (7.0) 0.23
 Intra-abdominal infection 7 (5.0) 6 (10.5) 0.20
 Surgical site infection 7 (5.0) 1 (1.8) 0.44
 CNS infection 1 (0.7) 0 (0) 1.00
Primary bacteremia 38 (27.0) 17 (29.8) 0.73
Nosocomial bacteremia 123/200 (61.5) 55/200 (27.5) 0.07
Shock when bacteremia 14 (9.9) 34 (59.6) < 0.01
Pitt bacteremia score 2.0 ± 2.5 4.7 ± 3.1 < 0.01
Pitt bacteremia score ≥ 4 32 (22.7) 28 (49.1) < 0.01
ICU-acquired infection 45 (31.9) 29 (50.9) 0.02
Inappropriate empirical antimicrobial therapy 96 (68.1) 34 (59.6) 0.32
Polymicrobial infection 40 (28.4) 16 (28.1) 1.00
Pseudomonas aeruginosa 76/115 (66.1) 39/115 (33.9) 0.08
Acinetobacter baumannii 24/35 (68.6) 11/35 (31.4) 0.69
Stenotrophomonas maltophilia 11/16 (68.7) 5/16 (31.3) 0.82
aData presented as mean ± standard deviation, n (%) or number of positive cases/total cases examined (%). CNS = Central nervous system; 
CVC = central venous catheter; ICU = intensive care unit.
were all independent risk factors for fatality in patients 
with GNF-GNB bacteremia.
Discussion
The incidence of GNF-GNB bacteremia in general and 
that caused by different GNF-GNB species in particular, 
varies from one hospital to another.1,13–15 Consistent with 
a previous report,13 P. aeruginosa was the most commonly 
encountered cause of BSI in CGMH-KS.
Our data show that GNF-GNB BSI may develop in 
patients of all ages, with a higher incidence in elderly 
patients (age > 65 years) (Table 1). In agreement with pre-
vious reports,16–18 the most frequently seen underlying 
diseases/conditions in patients with GNF-GNB BSI were 
solid tumors and steroid use. Although CVC-related 
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GNF-GNB BSI is not uncommon,19,20 the incidence of 
CVC-related GNF-GNB BSI in this study was remarkably 
low compared with other reports.21 CVC-related GNF-
GNB BSI may, therefore, have been under diagnosed at our 
institute, and further study is needed to clarify this; indeed, 
if this was the case, upon encountering a patient with 
BSIs due to GNF-GNB and skin flora alike (e.g. coagulase-
negative staphylococci), a careful evaluation is needed to 
determine whether or not that indwelling CVC should 
be removed.
Similar to other reports,2,22 P. aeruginosa was the most 
common GNF-GNB pathogen causing BSIs and was often 
nosocomially-acquired. A high mortality rate (> 33.9%) in 
patients with P. aeruginosa BSIs has been previously re-
ported.22 In general, the use of antimicrobial regimens 
lacking activity against the pathogenic microbes in criti-
cally ill patients is associated with greater hospital mor-
tality.23–25 It has also been reported that inappropriate 
empirical antimicrobial therapy for BSIs specifically 
caused by P. aeruginosa leads to a significantly higher mor-
tality rate and is an independent predictor of hospital 
mortality.26 However, this was not the case for empirical 
antimicrobial therapy for BSIs caused by GNF-GNB other 
than P. aeruginosa.21 Multi-drug resistance is not uncom-
mon among GNF-GNB, and may result from either in-
trinsic resistance and/or rapidly acquired resistance after 
antimicrobial exposure.5,6 Consequently, it is not unusual 
for patients with GNF-GNB BSI to be given inappropriate 
antibiotic(s) prescribed on an empirical basis before the 
pathogen is identified by culture tests.27 Therefore, it is 
very important to carefully tailor antibiotic therapy for 
GNF-GNB BSI based on susceptibility testing, and to iden-
tify the particular risk factors for fatality in this patient 
population.
Being a retrospective study, some limitations must to be 
addressed. First, the collection of specimens for culture was 
not based on a standardized protocol, resulting in some 
missing data (e.g. some CVC tips were not sent for culture), 
which may bias our assessment of the risk factors for acqui-
sition of GNF-GNB bacteremia. Second, the patients with 
GNF-GNB BSIs were not subject to standardized treat-
ments, which may have affected the final outcome.
Independent risk factors for fatality in GNF-GNB 
bacteremia found in this series included liver cirrhosis, 
hematologic malignancy, pneumonia, septic shock and 
ICU-acquired infections. They were reflective of the un-
derlying immunocompromise, and/or clinical severity of 
the affected patients,21 leading to substantial mortality. 
Because CVC placement and steroid use were found to pre-
dispose to GNF-GNB bacteremia, early removal of CVC 
and avoidance of steroid use may minimize acquisition of 
this infection, which is of particular importance in those 
patients at high risk for mortality once infected with 
GNF-GNB.
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